 |
1.Proliferation in
HHV-8-Positive Primary Effusion Lymphomas Is Associated
with Expression of HHV-8 Cyclin but Independent of
p27(kip1). |
|
2. Vinorelbine is an
effective and safe drug for AIDS-related Kaposi's
sarcoma: results of a phase II study. |
|
3. Role of brain biopsy
in the management of focal brain lesions in HIV-infected
patients. Gruppo Italiano Cooperativo AIDS & Tumori. |
|
4. Molecular profile of epstein-barr virus infection in
HHV-8-positive primary effusion lymphoma.
|
|
5. Lung carcinoma in 36 patients with human
immunodeficiency virus infection. |
|
6. Mutation of BAX occurs infrequently in acquired
immunodeficiency syndrome-related non-Hodgkin's
lymphomas. |
|
7. Idiopathic chronic
fatigue and chronic fatigue syndrome: a comparison of
two case-definitions. |
|
8. HAART is effective as anti-Kaposi's sarcoma therapy
only after remission has been induced by chemotherapy. |
|
9. Neoplastic complications of HIV infection. |
|
10. Therapy of non-small-cell lung cancer (NSCLC) in
patients with HIV infection. |
|
11. Interactions of Antineoplastic Chemotherapy with
Zidovudine Pharmacokinetics in Patients with HIV-Related
Neoplasms. |
|
12. Hodgkin's disease in HIV-infected individuals.
|
|
13. Combination therapy with alpha interferon and
lamivudine in patients with chronic hepatitis B and HIV
infection. |
|
14. Kinetics of lymphokine production in HIV+ patients
treated with highly active antiretroviral therapy and
interleukin 2. |
|
15. Debate on Di Bella therapy. |
|
16.
Evaluation study of the opinion on Di Bella's multimodal
therapy of patients with tumors. |
|
17.
Immunological changes in peripheral blood and in
lymphoid tissue after treatment of HIV-infected subjects
with highly active anti-retroviral therapy (HAART) or
HAART + IL-2. |
|
18.
A risk and benefit assessment of treatment for
AIDS-related Kaposi's sarcoma. |
|
19.
The effects of CD40 ligation on peripheral blood
mononuclear cell interleukin-12 and interleukin-15
production and on monocyte CD14 surface antigen
expression in human immunodeficiency virus-positive
patients. |
|
20.
AIDS-associated Kaposi's sarcoma is more aggressive in
women: a study of 54 patients. |
|
21.
Hodgkin's disease in 35 patients with HIV infection: an
experience with epirubicin, bleomycin, vinblastine and
prednisone chemotherapy in combination with
antiretroviral therapy and primary use of G-CSF. |
|
22.
Human immunodeficiency virus-associated Hodgkin's
disease derives from post-germinal center B cells. |
|
23.
Dynamics of provirus load and lymphocyte subsets after
interleukin 2 treatment in HIV-infected patients. |
|
24.
Condom use in female sex workers in Italy. |
|
25.
Concomitant therapy with subcutaneous interleukin-2 and
zidovudine plus didanosine in patients with early stage
HIV infection. |
|
26. The pathologic
spectrum of AIDS-related non-Hodgkin’s lymphomas. |
|
27. Major cardiovascular
events following infusional 5-fluorouracil and cisplatin
antineoplastic therapy. |
|
28. Neoplastic disease. |
|
29. The role and activity
of an Italian volunteer organization providing
information and emotional support for patients with
cancer. |
|
30.
Discordant hhv8 detection in a young hiv-negative
patient with kaposi's sarcoma and sarcoidosis. |
|
31. Chronic
hepatitis C in HIV-coinfected patients: feasibility and
efficacy of interferon-alpha2b and ribavirin combination
therapy. |
|
32.
Hodgkin's
disease: clinical presentation and treatment. |
|
33. A 20-year experience
on malignant lymphomas in patients aged 70 and older at
a single institute. |
|
34. A 20-year experience
on malignant lymphomas in patients aged 70 and older at
a single institute. |
|
35. Primary effusion
lymphoma cell lines harbouring human herpesvirus type-8. |
|
36. Characterization of a
novel HHV-8-positive cell line reveals implications for
the pathogenesis and cell cycle control of primary
effusion lymphoma. |
|
37. Human immunodeficiency
virus-associated Hodgkin's disease. |
|
38. Epidemiological,
biological and clinical features of HIV-related
lymphomas in the era of highly active antiretroviral
therapy. |
|
39. Insights into the
reasons for discontinuation of the first highly active
antiretroviral therapy (HAART) regimen in a cohort of
antiretroviral naive patients. ICONA Study Group.
Italian Cohort of Antiretroviral Naive Patients. |
|
40. Stanford V regimen and
concomitant highly active antiretroviral therapy is
feasible and active in patients with Hodgkin's disease
and HIV infection. |
|
41. Effects of 2-year
antiretroviral combination therapies on HIV-1 DNA levels. |
|
42. Effects of therapy
with highly active anti-retroviral therapy (HAART) and
IL-2 on CD4+ at lymphocyte apoptosis in HIV+patients. |
|
43. Plasma viral load
concentrations in women and men from different exposure
categories and with known duration of HIV infection. |
|
44. Concomitant
cyclophosphamide, doxorubicin, vincristine and
prednisone chemotherapy plus highly active
antiretroviral therapy in patients with human
immunodeficiency virus-related non-Hodgkin lymphoma. |
|
45. Absence of an effect
of herpes simplex virus type 2 infection on HIV disease
progression: data from a cohort of HIV-positive
individualks with known date of seroconversion. |
|
46. Hodgkin's disease:
clinical presentation and treatment. |
|
47. A 20-year experience
on malignant lymphomas in patients aged 70 and older at
a single institute. |
|
48. Discordant hhv8
detection in a young HIV-negative patient with Kaposi's
sarcoma and sarcoidosis. |
|
49. Chronic hepatitis C in
HIV-coinfected patients: feasibility and efficacy of
interferon-alpha2b and combination therapy. |
|
50. Standard chemotherapy
with or without high-dose chemotherapy for aggressive
non-Hodgkin's lymphoma: randomized phase III EORTC Study. |
|
51. Expression profile of
MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel
histogenetic subsets of human immunodeficiency
virus-related lymphomas. |
|
52. Incidence of invasive
cervical cancer in a cohort of HIV-seropositive women
before and after the introduction of highly active
antiretroviral therapy. |
|
53. Response to highly
active antiretroviral therapy according to duration of
HIV infection. |
|
54. Lymphocyte subsets and
viral load in patients with HIV-associated non-Hodgkin's
lymphoma treated with anti-CD20 monoclonal antibody and
chemotehrapy. |
|
55. Human immunodeficiency
virus-related non-Hodgkin's lymphoma: activity of
infusional cyclophosphamide, doxorubicin, and etoposide
as second-line chemotherapy in 40 patients. |
|
56. Impact of HAART on the
clinical management of AIDS-related cancers. |
|
57. Clinical aspects and
management of Hodgkin's disease and other tumors in
HIV-infected individuals. |
|
58. Chronic hepatitis C in
HIV-coinfected patients: feasibility and sustained
efficacy of therapy with interferon alpha-2b and
ribavirin. |
|
59. Cervical cancer in
HIV. |
|
60. Management of
hematologic malignancies in the elderly: 15-year
experience at the Aviano Cancer Center, Italy. |
|
61. I linfomi
non-Hodgkin-HIV sistemici nell'era dell'HAART. Storia
naturale. |
|
62. Low frequency of
severe hepatotoxicity and association with HCV
coinfection in HIV-positive patients treated with HAART. |
|
63.
Infusional CDE with
rituximab for the treatment of human immunodeficiency
virus-associated non-Hodgkin's lymphoma: preliminary
results of a phase I/II study. |
|
64. Neoplastic
complications of AIDS. |
|
65.
AIDS-related tumors:
integrating antiviral and anticancer therapy. |
|
66.
Relevance of intraocular
involvement in the management of primary central nervous
system lymphomas. |
|
67.
Elderly head and neck
(H-N) cancer patients: a monoinstitutional series. |
|
68.
Non-Hodgkin's lymphoma in
the elderly. |
|
69.
Hodgkin's disease in the
elderly: current status and future directions. |
|
70.
A multicenter study of
treatment of primary CNS lymphoma. |
|
71. Intensified CHOP
regimen in aggressive lymphomas: maximal dose intensity
and dose intensity of doxorubicin and cyclophosphamide |
|
72. Differentation between
non-Hodgkin's lymphoma ercurrence and second primary
lymphoma by VDJ rearrangement analysis. |
|
73. Expression of
cyclin-dependent kinase inhibitor p27Kip1 in
AIDS-related diffuse large-cell lymphomas is associated
with Epstein-Barr virus-encoded latent membrane protein
1. |
|
74. Stanford V regimen and
concomitant HAART in 59 patients with Hodgkin disease
and HIV infection. |
|
75. Cancer-related fatigue. |
|
76. Rituximab and
chemotherapy is highly effective in patients with
CD20-positive non-Hodgkin's lymphoma. |
|
77. No Protective effects
of acyclovir on HIV disease progression in a cohort of
HSV-2-HIV-infected individuals. |
|
78. Prognosis of
HIV-1-infected patients starting highly active
antiretroviral therapy: a collaborative analysis of
prospective studies. |
|
79. Effect of multiple
herpesvirus infections on the progression of HIV disease
in a cohort of HIV seroconverters. |
|
80. Comprehensive
geriatric evaluation in elderly patients with lymphoma:
feasibility of a patient-tailored treatment plan. |
|
81.Rituximab and
chemotherapy is highly effective in patients with
CD20-positive non Hodgkin's lymphoma and HIV infection. |
|
82. High international
prognostic score predicts a worse outcome for patients
with Hodgkin's disease and HIV infection: results of a
prospective study with Stanford V regimen. |
|
83. Interferon-gamma
secretion and perforin expression are impaired in CD8+ T
lymphocytes from patients with undifferentiated
carcinoma of nasopharyngeal type. |
|
84. . Prognosis of
HIV-1-infected patients starting highly active
antiretroviral therapy: a collaborative analysis of
prospective studies. |
|
85.
Involved-field radiotherapy for advanced Hodgkin's
lymphoma. |
|
87.
AIDS-related Kaposi's sarcoma: evaluation of potential
new prognostic factors and assessment of the AIDS
Clinical Trial Group Staging System in the HAART era -
the Italian Cooperative Group on AIDS and Tumors
and the Italian Cohort of Patients Naive from
Antiretrovirals |
|
88. Therapeutic approaches
to AIDS-related malignancies |
|
89. Impact of concomitant antiblastic chemotherapy and
highly active antiretroviral therapy on human
immunodeficiency virus (HIV) viremia and genotyping in
HIV-infected patients with non-Hodgkin's lymphoma. |
|
90. Improvement of
systemic human immunodeficiency virus-related
non-Hodgkin lymphoma outcome in the era of highly active
antiretroviral therapy. |
|
91.Clinical
features and outcome of primary effusion lymphoma in
HIV-infected patients: a single institution study |
|
92.
High-dose therapy and autologous peripheral-blood
stem-cell transplantation as salvage treatment for
HIV-associated lymphoma in patients receiving highly
active antiretroviral therapy. |
|
93.
Impact of highly active antiretroviral therapy on the
presenting features and outcome of patients with
acquired immunodeficiency syndrome-related Kaposi’s
sarcoma. |
|
94.
Outcome in patients with no-hodgkin lymphoma and with
or without human immunodeficiency virus infection |
|
95.
Long-term efficacy of the CHVmP/BV regimen used for
aggressive non-Hodgkin's lymphoma in three randomised
EORTC trials |
|
96.
Mitoxantrone, vinorelbine and prednisone (MVD) in the
treatment of metastatic hormonoresistant prostate
cancer--a phase II trial |
|
97.
Virological efficacy in
HIV-infected patients affected by non-Hodgkin lymphoma,
treat with antiblastic chemotherapy and highly active
antiretroviral therapy |
|
98.
Efficacy and safety of combined treatment with
pegylated.IFN-alpha2b plus rebavirin in HIV-hepatitis C
virus-co-infected patients |
|
99. Improving information
to Italian cancer patients: results of a randomized
study |
|
100. Tumori solidi |
|
101. HIV-related
non-Hodgkin's lymphoma (HIV-NHL) in the era of highly
active antiretroviral therapy (HAART): some still
unanswered questions for clinical management.
|
|
102. Rituximab-CHOP or 2
weekly CHOP + G-CSF in aggressive lymphoma of the
elderly? |
|
103. Hepatitis C virus
infection does not prevent autologous bone marrow
transplantation in HIV related non-Hodgkin's lymphoma
|
|
104. Fatigue in cancer
patients receiving chemotherapy: analysis of published
studies.
|
|
Fatigue in Cancer - review
|
|
105. Rituximab plus
infusional cyclophosphamide, doxorubicin and etoposide (R-CDE)
in HIV-associated non-Hodgkin's lymphoma: pooled results
from three phase II trials.
|
|
106. Effect of highly
active antiretroviral therapy (HAART) on
pharmacokinetics and pharmacodynamics of doxorubicin in
patients with HIV-associated non-Hodgkin's lymphoma.
|
|
107.Treatment of head and
neck cancer in elderly patients: state of the art and
guidelines.
|
|
108. Kaposi's
Sarcoma-Associated Herpesvirus/Human Herpesvirus Type
8-Positive Solid Lymphomas: A Tissue-Based Variant of
Primary Effusion Lymphoma.
|
|
109.Dysphonia as an
unusual toxic event of oxaliplatin-based chemotherapy. |
|
110.Pharmacokinetic
interaction between chemotherapy for non-Hodgkin's
lymphoma and protease inhibitors in HIV-1-infected
patients.
|
|
111.Hepatitis C virus and
non-Hodgkin's lymphoma 10 years later. |
|
112.Is high-dose
chemotherapy with peripheral stem cell rescue a suitable
option for elderly patients affected by aggressive
non-Hodgkin's lymphoma?
|
|
113.Cancer Prevention and
Early Diagnosis in HIV-Positive Individuals. |
|
114.Highly Active
Antiretroviral Therapy in AIDS-Associated Kaposi's
Sarcoma (KS): Implications for the Design of Therapeutic
Trials in Patients With Advanced Symptomatic KS. |
|
115. Characterization of
immunologic and virological parameters in HIV-infected
patients with primary effusion lymphoma during
antiblastic therapy and highly active antiretroviral
therapy. |
|
116. Treatment with
peg-interferon alfa-2b and ribavirin of hepatitis C
virus-associated mixed cryoglobulinemia: a pilot study. |
|
117. Neoadjuvant
accelerated chemotherapy followed by hyperfractionated
radiation therapy in patients with operable, locally
advanced head and neck carcinoma. |
|
118.Trends in cancer incidence rates among HIV-infected
patients. |
|
119. Regression of
low-grade non-Hodgkin's lymphoma after treatment with
pegylated interferon plus ribavirin in hepatitis C virus
infection. |
|
120. Cancer and aging: are
there any differences in the information needs of
elderly and younger patients? Results from an Italian
observational study.
|
|
121. Rituximab for
HIV-associated lymphoma: weighing the benefits and risks.
|
|
122.Gefitinib in patients
with non-small cell lung cancer: Symptomatic improvement
within a few days.
|
|
123. KSHV/HHV-8 associated
lymph node based lymphomas in HIV seronegative subjects.
Report of two cases with anaplastic large cell
morphology and plasmablastic immunophenotype. |
|
124. Pretreatment quality
of life and functional status assessment significantly
predict survival of elderly patients with advanced
non-small-cell lung cancer receiving chemotherapy: a
prognostic analysis of the multicenter Italian lung
cancer in the elderly study. |
|
125.Late non-neoplastic
events in patients with aggressive non-Hodgkin's
lymphoma in four randomized European Organisation for
Research and Treatment of Cancer trials. |
|
126.Patients with HIV with
Burkitt's lymphoma have a worse outcome than those with
diffuse large-cell lymphoma also in the highly active
antiretroviral therapy era. |
|
127.Liver resection of
metastasis by colorectal cancer in a HIV patient. |
|
128.Oxaliplatin-based
chemotherapy in association with highly active
antiretroviral therapy in metastatic colorectal cancer
HIV-infected patients |
|
129.Vinorelbine and
prednisone in frail elderly patients with
intermediate-high grade non-Hodgkin's lymphomas. |
|
130.Prognostic factors in
human herpesvirus 8-related lymphoproliferative
disorders associated with HIV infection. |
|
131.Keynote comment:
reimbursement for molecularly targeted anticancer agents |
|
132. A spindle cell
variant of diffuse large B-cell lymphoma possesses
genotypic and phenotypic markers characteristic of a
germinal center B-cell origin. |
|
133. AIDS-related
non-Hodgkin's lymphoma: final analysis of 485 patients
treated with risk-adapted intensive chemotherapy. |
|
134. Adding gemcitabine to
paclitaxel/carboplatin combination increases survival in
advanced non-small-cell lung cancer: results of a phase
II-III study. |
|
135. Treatment of elderly
cancer patients: a planet in evolution. |
|
136. Multidisciplinary
approach in a HIV/HCV-positive patient with liver
metastases by colorectal cancer in the HAART era. |
|
137. Interleukin-2
continuous infusion and angiogenesis surrogate markers
in metastatic renal cell carcinoma. |
|
138.Colorectal cancer
screening in HIV-infected patients 50 years of age and
older: missed opportunities for prevention. |
|
139.Don't deny liver
transplantation to HIV patients with hepatocellular
carcinoma in the highly active antiretroviral therapy
era. |
|
140. Insight into the
treatment of cancer in older patients: Developments in
the last decade. |
|
141.FOLFOX2 regimen in the
treatment of advanced colorectal cancer: a comparison
between elderly and young patients. |
|
142.Metastatic
angiosarcoma of the kidney: a case report with treatment
approach and review of the literature. |
|
143. Combined-modality
therapy for clinical stage I or II Hodgkin's lymphoma:
long-term results of the European Organisation for
Research and Treatment of Cancer H7 randomized
controlled trials. |
|
144.Oxaliplatin and
capecitabine (Xelox) in association with highly active
antiretroviral therapy in advanced hepatocarcinoma |
|
145.Impact of involved
field radiotherapy in partial response after
doxorubicin-based chemotherapy for advanced aggressive
non-Hodgkin's lymphoma. |
|
146.What elderly cancer
patients want to know? Differences among elderly and
young patients |
|
147.Gefitinib in the
treatment of elderly patients with advanced non-small
cell lung cancer (NSCLC). |
|
148.A pilot project of a
cancer patient library in Italy: results of a
customer-satisfaction survey and its products. |
|
149.
Ifosfamide,
gemcitabine, and vinorelbine: a new induction regimen
for refractory and relapsed Hodgkin's lymphoma.
Haematologica. 2007 Jan;92(1):35-41.
|
|
150.
Reduced-intensity
allogeneic transplantation in patients with refractory
or progressive Hodgkin's disease after high-dose
chemotherapy and autologous stem cell infusion.
Eur J
Haematol. 2007 Jan 23 |
|
151.
Phase II trial of
CHOP plus rituximab in patients with HIV-associated
non-Hodgkin's lymphoma.
J Clin Oncol. 2007 Feb 20;25(6):e7. |
|
152.Cetuximab/targeted
chemotherapy in an HIV-positive patient with metastatic
colorectal cancer in the HAART era: a case report.
J Chemother. 2007 Jun;19(3):343-6. |
|
153.Lopinavir-Ritonavir
Dramatically Affects the Pharmacokinetics of Irinotecan
in HIV Patients With Kaposi's Sarcoma.
Clin Pharmacol Ther. 2007 Aug 22 |
|
154.Role
of the HLA class II: HCV-related disorders.
Ann N Y Acad Sci. 2007 Jun;1107:308-18.
|
|
155. IGEV
regimen and a fixed dose of lenograstim: an effective
mobilization regimen in pretreated Hodgkin's lymphoma
patients.
Bone Marrow
Transplant. 2007 Oct 1 |
|
156.Recent
thymic emigrants in lymphoma patients with and without
human immunodeficiency virus infection candidates for
autologous peripheral stem cell transplantation.
Clin
Exp Immunol. 2007 Oct 11 |
|
157.High
relapse rate after a brief chemotherapy course and
involved-field radiotherapy in early-stage Hodgkin
lymphoma.
Leuk Lymphoma. 2007 Oct 9 |
|
158.
Bearz A, Serraino D, Fratino L, Berretta M, Tirelli U.
Recent improvement in the survival of patients with
advanced nonsmall cell lung cancer enrolled in phase III
trials of first-line, systemic chemotherapy.
Cancer. 2007 Oct 25 |
|
159.Chemotherapy plus involved-field radiation in
early-stage Hodgkin's disease.
N Engl J Med. 2007 Nov 8;357(19):1916-27 |
|
160.Pemetrexed single agent in previously treated
non-small cell lung cancer: A multi-institutional
observational study.
|
|
Dig Liver Dis. 2007 Sep; 39
Suppl 1: S102-6.
|
|
|
|
163. MUC-1 (CA
15-3 antigen) as a highly reliable predictor of response
to EGFR inhibitors in patients with bronchioloalveolar
carcinoma: an experience on 26 patients.
Int J Biol Markers. 2007 Oct-Dec;22(4):307-11. |
|
164.Clinical
management of long-term cancer survivors.
J Clin Oncol. 2008
Jan 1;26(1):161-2 |
|
165.
Can the caregiver replace his/her elderly cancer patient
in the physician-patient line of communication?
Support Care Cancer. 2008 Jan 29 |
|
166. Distinct
functional significance of Akt and mTOR constitutive
activation in mantle cell lymphoma.
Blood. 2008 May
15;111(10):5142-51. |
|
167. Use of
nucleoside reverse transcriptase inhibitors and risk of
myocardial infarction in HIV-infected patients enrolled
in the D:A:D study: a multi-cohort collaboration.
Lancet. 2008 Apr 26;371(9622):1417-26. |
|
168.
Self-reported sexual dysfunction is frequent among
HIV-infected persons and is associated with suboptimal
adherence to antiretrovirals.
AIDS Patient Care STDS. 2008 Apr;22(4):291-9. |
|
169. Changes
over time in risk factors for cardiovascular disease and
use of lipid-lowering drugs in HIV-infected individuals
and impact on myocardial infarction.
Clin Infect
Dis. 2008 Apr 1;46(7):1101-10. |
|
170.Cancer
survivorship: a challenge for the European
oncologists.Ann Oncol. 2008 Jun 4 |
|
171. Molecular
analysis of immunoglobulin variable genes in human
immunodeficiency virus-related non-Hodgkin's lymphoma
reveals implications for disease pathogenesis and
histogenesis. Haematologica. 2008 Jun 12 |
|
172.Adjuvant
radiotherapy on older and oldest elderly rectal cancer
patients.Arch Gerontol Geriatr. 2008 Jun 21 |
|
173.FOLFOX-4
regimen with concomitant highly active antiretroviral
therapy in metastatic colorectal cancer HIV-infected
patients: a report of five cases and review of the
literature.Cancer Invest. 2008 Jul;26(6):610-4. Review. |
|
174.
Bevacizumab plus irinotecan-, fluorouracil-, and
leucovorin-based chemotherapy with concomitant HAART in
an HIV-positive patient with metastatic colorectal
cancer.
Onkologie. 2008
Jul;31(7):394-7 |
|
175. FOSFOX2 in
the treatment of advanced colorectal cancer: a
comparison between elderly and middle aged patients.J
Chemother. 2008 Aug;20(4):503-8. |
|
176.AIDS. 2008 Sep 12;22(14):1769-78
Genetic polymorphisms
differently influencing the emergence of atrophy and fat
accumulation in HIV-related lipodystrophy. |
|
177.
Br J Cancer. 2008 Sep
9.
Clinical outcome and prognostic factors for patients treated
within the context of a phase I study: the Royal Marsden
Hospital experience. |
|
178.
Tumori. 2008
Jul-Aug;94(4):589-91.
Unusual presentation of metastatic hepatocellular
carcinoma in an HIV/HCV coinfected patient: case report
and review of the literature. |
|
179.
HIV-induced
immunodeficiency and mortality from AIDS-defining and
non-AIDS-defining malignancies.
AIDS. 2008 Oct 18;22(16):2143-53. |
|
180. Does
short-term virologic failure translate to clinical
events in antiretroviral-naïve patients initiating
antiretroviral therapy in clinical practice?
AIDS. 2008 Nov 30;22(18):2481-92. |
|
181. Cancer
in the elderly: The caregivers' perception of senior
patients' informational needs.
Arch Gerontol Geriatr. 2008 Dec 11. |
|
182.
Pegylated-interferon plus ribavirin for HCV-positive
indolent non-Hodgkin lymphomas
Br J Haematol.
2009 Feb 12. |
|
183. Variable
impact on mortality of AIDS-defining events diagnosed
during combination antiretroviral therapy: not all
AIDS-defining conditions are created equal.
Clin Infect Dis. 2009 Apr 15;48(8):1138-51. |
|
184. Plasma
HHV-8 viral load in HHV-8-related lymphoproliferative
disorders associated with HIV infection.
J Med Virol. 2009 May;81(5):888-96. |
|
185.
Safety
and feasibility of radiotherapy treatment in elderly
non-small-cell lung cancer (NSCLC) patients.
Arch Gerontol Geriatr. 2009 Apr 30.
|
|
186.
Leiomyosarcoma
of the parotid gland in an HIV-positive patient:
therapeutic approach, clinical course and review of the
literature.
J Chemother. 2009 Apr;21(2):215-8. |
|
187.
Human
immunodeficiency virus-associated precursor
T-lymphoblastic leukemia/lymphoblastic lymphoma: report
of a case and review of the literature.
Hum Pathol.
2009 May 6. |
|
188. High dose
therapy and autologous peripheral blood stem cell
transplantation as salvage treatment for AIDS-related
lymphoma: long term results of the GICAT study with
analysis of prognostic factors.
Blood. 2009 May
18. |
|
189.Clinical
presentation and outcome of colorectal cancer in
HIV-positive patients: a clinical case-control study.
Onkologie. 2009 Jun;32(6):319-24.
Epub 2009 May 14.
Comment in: Onkologie. 2009 Jun;32(6):306-7. |
|
190.
Viral interference between hepatitis B, C, and D
viruses in dual and triple infections in HIV-positive
patients.
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81.
|
|
191.
Risk of developing specific AIDS-defining illnesses in patients
coinfected with HIV and hepatitis C virus with or without liver
cirrhosis.
Clin Infect Dis. 2009 Aug 15;49(4):612-22.
Comment in: Clin Infect Dis. 2009 Aug 15;49(4):623-5.
|
|
192.
Glioblastoma in elderly patients: Safety and efficacy of
adjuvant radiotherapy with concomitant temozolomide.
Arch Gerontol Geriatr. 2009 Jul 21.
|
|
193.
Activity of
Pemetrexed on brain metastases from Non-Small Cell
.Lung
Cancer. 2009 Jul 24.
|
|
194. Market
and patient access to new oncology products in Europe: a
current, multidisciplinary perspective.
Ann Oncol. 2009 Aug;20(8):1445.
Comment on: Ann Oncol. 2009 Mar;20(3):403-12.
|
|
195.
Assessing cancer-related fatigue: the psychometric properties of
the Revised Piper Fatigue Scale in Italian cancer inpatients.
Support
Care Cancer. 2009 Sep 26. |
|
196.
Quality of life after successful treatment of
early-stage Hodgkin's lymphoma: 10-year follow-up of the
EORTC-GELA H8 randomised controlled trial.
Lancet Oncol. 2009
Oct 12. |
|
197. Genome wide DNA-profiling of HIV-related B-cell lymphomas.
Br
J
Haematol. 2009 Oct 12. |
|
198.
Management
of immunocompetent patients with primary central nervous
system lymphoma.
Clin Lymphoma Myeloma. 2009 Oct;9(5):353-64. |
|
199.
Mortality from
HIV and TB coinfections is higher in Eastern Europe than
in Western Europe and Argentina.
Collaborators (353)
AIDS. 2009 Nov 27;23(18):2485-95. |
|
200.
AIDS-Related Kaposi's Sarcoma: State of the Art and Therapeutic
Strategies.
Curr
HIV Res. 2009 Nov;7(6):634-8. |
|
201.
Comprehensive cancer control-research & development: knowing what we
do and doing what we know.
Tumori. 2009 Sep-Oct;95(5):610-22. |
|
202.
Biomarkers in
neuroendocrine tumors.
Front Biosci (Schol Ed). 2010 Jan 1;2:332-42. |
|
203.
Biological and
clinical markers in colorectal cancer: state of the art.
Front Biosci (Schol Ed). 2010 Jan 1;2:422-31. |
|
204.
Safety and
efficacy of radiotherapy treatment in elderly patients
with localized prostate cancer: A retrospective
analysis.
Arch Gerontol Geriatr. 2009 Dec 29. |
|
205.
Phase 2 study
of intrathecal, long-acting liposomal cytarabine in the
prophylaxis of lymphomatous meningitis in human
immunodeficiency virus-related non-Hodgkin lymphoma.
Cancer. 2010 Jan 27.
|
|
206.
Predictive
Value of HIV Type 1 DNA Levels on Overall Survival in
HIV-Related Lymphoma Patients Treated with High-Dose
Chemotherapy (HDC) Plus Autologous Stem Cell
Transplantation (ASCT).
AIDS Res Hum Retroviruses. 2010 Feb;26(2):245-51. |
|
207. Clinical
presentation and outcome of colorectal cancer in
HIV-positive patients: a clinical case-control study.
Onkologie. 2009 Jun;32(6):319-24. |
Indice delle pubblicazioni
Home Page
